132 related articles for article (PubMed ID: 26783933)
1. Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711.
Loeb S; Lambe M; Stattin P
J Urol; 2016 Apr; 195(4 Pt 1):1172-3. PubMed ID: 26783933
[No Abstract] [Full Text] [Related]
2. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Seftel AD
J Urol; 2016 Mar; 195(3):713. PubMed ID: 26887740
[No Abstract] [Full Text] [Related]
3. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Penson DF
J Urol; 2015 Dec; 194(6):1710-1. PubMed ID: 26582698
[No Abstract] [Full Text] [Related]
4. Words of Wisdom. Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Tasian GE; Cooperberg MR
Eur Urol; 2016 Feb; 69(2):374-5. PubMed ID: 26758522
[No Abstract] [Full Text] [Related]
5. Words of Wisdom. RE: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Damber JE
Eur Urol; 2015 Dec; 68(6):1102. PubMed ID: 26545574
[No Abstract] [Full Text] [Related]
6. Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma.
Loeb S; Folkvaljon Y; Lambe M; Robinson D; Garmo H; Ingvar C; Stattin P
JAMA; 2015 Jun 23-30; 313(24):2449-55. PubMed ID: 26103029
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.
Lian Y; Yin H; Pollak MN; Carrier S; Platt RW; Suissa S; Azoulay L
Eur Urol; 2016 Nov; 70(5):808-815. PubMed ID: 27178449
[TBL] [Abstract][Full Text] [Related]
8. [Erectile dysfunction, PDE5A inhibitors and melanoma].
Schmutz JL
Ann Dermatol Venereol; 2015 Dec; 142(12):800-1. PubMed ID: 26293983
[No Abstract] [Full Text] [Related]
9. Sildenafil may elevate melanoma risk.
Grichnik JM
Dermatol Ther; 2014; 27(5):313. PubMed ID: 25285874
[No Abstract] [Full Text] [Related]
10. Sexual dysfunction: PDE5i and melanoma-correlation is not causation.
Stone L
Nat Rev Urol; 2015 Aug; 12(8):418. PubMed ID: 26171805
[No Abstract] [Full Text] [Related]
11. Role of sildenafil in melanoma incidence and mortality.
Robinson JK
JAMA Intern Med; 2014 Jun; 174(6):970-1. PubMed ID: 24710720
[No Abstract] [Full Text] [Related]
12. Re: Prophylactic Sildenafil Citrate Improves Select Aspects of Sexual Function in Men Treated with Radiotherapy for Prostate Cancer: M. J. Zelefsky, D. Shasha, R. D. Branco, M. Kollmeier, R. E. Baser, X. Pei, R. Ennis, R. Stock, N. Bar-Chama and J. P. Mulhall J Urol 2014; 192: 868-874.
Zilli T; Miralbell R
J Urol; 2015 Aug; 194(2):600-1. PubMed ID: 25958020
[No Abstract] [Full Text] [Related]
13. Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
Houslay MD
Trends Cancer; 2016 Apr; 2(4):163-165. PubMed ID: 28741569
[TBL] [Abstract][Full Text] [Related]
14. Re: Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. A. R. McCullough, W. G. Hellstrom, R. Wang, H. Lepor, K. R. Wagner and J. D. Engel. J Urol 2010; 183: 2451-2456.
Levinson AW
J Urol; 2011 Apr; 185(4):1540-1; author reply 1540-1. PubMed ID: 21345457
[No Abstract] [Full Text] [Related]
15. Re: Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Seftel A
J Urol; 2013 Oct; 190(4):1340. PubMed ID: 24029345
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of phosphodiesterase-5 inhibitors for treating erectile dysfunction in kidney transplant recipients: a meta-analysis.
Fanbin L; Mei Y; Yan Z; Yirong Y; Shaoling Z; Yong C; Peng X
Exp Clin Transplant; 2014 Jun; 12(3):184-9. PubMed ID: 24907716
[TBL] [Abstract][Full Text] [Related]
17. [Psychogenic erectile dysfunction and phosphodiesterase inhibitors type 5].
Pushkar DY; Segal AS
Urologiia; 2016 Dec; (6):158-163. PubMed ID: 28248063
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
Dorsey P; Keel C; Klavens M; Hellstrom WJ
Expert Opin Pharmacother; 2010 May; 11(7):1109-22. PubMed ID: 20402554
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for extracorporeal shock wave therapy for erectile dysfunction unresponsive to phosphodiesterase type 5 inhibitors?
Zou ZJ; Liu ZH; Tang LY; Lu YP
World J Urol; 2017 Jan; 35(1):167-171. PubMed ID: 27447990
[No Abstract] [Full Text] [Related]
20. Sexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: an Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaire.
Tsujimura A; Kiuchi H; Soda T; Takezawa K; Okuda H; Fukuhara S; Takao T; Nonomura N; Miyagawa Y
Int J Urol; 2014 Aug; 21(8):821-5. PubMed ID: 24661267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
